This is a study for treatment-naïve HIV patients. This study is comparing the safety and efficacy of a new drug combination (GS-9883/FTC/TAF) to Dolutegravir + FTC/TAF. The trial is expected to last 2 years. The study sponsor will cover all cost related to the study including office visits, labs and medications.
Who may be Eligible
Patients may be eligible if they meet the following: Adults (18 years or older); HIV positive with no history of therapy; Normal maintenance labs and EKG; Agree to not become pregnant or father a child during the study; Agree to birth control methods as outlined by the study protocol; have no new infections in the past month that required hospitalization or IV therapy; No history of cancer in the past 5 years; New acute hepatitis B is an exclusion; Active tuberculosis is an exclusion.